These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 9548597

  • 21. Compound heterozygotes for a novel mutation, apo E1 Nagoya (Arg142Ser) and Apo E2 (Arg158Cys), with severe type III hyperlipoproteinemia and familial hypercholesterolemia.
    Sakuma N, Hibino T, Saeki T, Nagata T, Sato T, Okuda N, Matsunaga A, Sasaki J.
    J Atheroscler Thromb; 2014; 21(9):983-8. PubMed ID: 24953047
    [Abstract] [Full Text] [Related]

  • 22. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
    Dong LM, Innerarity TL, Arnold KS, Newhouse YM, Weisgraber KH.
    J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin.
    Zhao SP, Smelt AH, Van den Maagdenberg AM, Van Tol A, Vroom TF, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van 't Hooft FM.
    Arterioscler Thromb; 1994 Nov; 14(11):1705-16. PubMed ID: 7947593
    [Abstract] [Full Text] [Related]

  • 25. Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.
    de Beer F, van Dijk KW, Jong MC, van Vark LC, van der Zee A, Hofker MH, Fallaux FJ, Hoeben RC, Smelt AH, Havekes LM.
    Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1800-6. PubMed ID: 10894820
    [Abstract] [Full Text] [Related]

  • 26. Contribution of APOE Genetic Variants to Dyslipidemia.
    Bea AM, Larrea-Sebal A, Marco-Benedi V, Uribe KB, Galicia-Garcia U, Lamiquiz-Moneo I, Laclaustra M, Moreno-Franco B, Fernandez-Corredoira P, Olmos S, Civeira F, Martin C, Cenarro A.
    Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1066-1077. PubMed ID: 37051929
    [Abstract] [Full Text] [Related]

  • 27. Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).
    Mann WA, Lohse P, Gregg RE, Ronan R, Hoeg JM, Zech LA, Brewer HB.
    J Clin Invest; 1995 Aug; 96(2):1100-7. PubMed ID: 7635945
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia).
    Chappell DA.
    J Clin Invest; 1989 Dec; 84(6):1906-15. PubMed ID: 2556448
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
    Havekes L, de Wit E, Leuven JG, Klasen E, Utermann G, Weber W, Beisiegel U.
    Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia.
    de Beer F, Stalenhoef AF, Hoogerbrugge N, Kastelein JJ, Gevers Leuven JA, van Duijn CM, Havekes LM, Smelt AH.
    Arterioscler Thromb Vasc Biol; 2002 Feb 01; 22(2):294-9. PubMed ID: 11834531
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Apolipoprotein E2 transgenic rabbits. Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis.
    Huang Y, Schwendner SW, Rall SC, Sanan DA, Mahley RW.
    J Biol Chem; 1997 Sep 05; 272(36):22685-94. PubMed ID: 9312550
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.
    Mahley RW, Huang Y, Rall SC.
    J Lipid Res; 1999 Nov 05; 40(11):1933-49. PubMed ID: 10552997
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.